capmatinib (Tabrecta) Report issue

Small molecule Orphan Drug FDA Approved FDA Breakthrough Therapy FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.   Wikipedia

Chemistry

  • SMILES: CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F
  • InChIKey: LIOLIMKSCNQPLV-UHFFFAOYSA-N
  • Mol. Mass: 412.43
  • ALogP: 3.43
  • ChEMBL Molecules:
    capmatinib  
    capmatinib hydrochloride  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$119.8795 - $158.6571
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

capmatinib | inc280 | inc-280 | incb028060 | incb-28060 | nvp-inc280

Organizations (22)

Research & Development (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (24)

Approved Indications (1)


 

Carcinoma, Non-Small-Cell Lung

Experimental Indications - Clinical Trial Phases 1-4 (24)


 

Biomarkers (Phase 2)

Breast Neoplasms (Phase 1)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 4)

Carcinoma, Renal Cell (Phase 1)

Colorectal Neoplasms (Phase 1/Phase 2)

Esophageal Neoplasms (Phase 2)

Glioblastoma (Phase 1/Phase 2)

Gliosarcoma (Phase 1)

Kidney Neoplasms (Phase 2)

Liver Diseases (Phase 1)

Lung Neoplasms (Phase 2)

Melanoma (Phase 2)

Mutation (Phase 2)

Neoplasms (Phase 4)

Oncogene Proteins (Phase 2)

Oncogenes (Phase 2)

Proto-Oncogene Proteins B-raf (Phase 2)

Proto-Oncogene Proteins c-met (Phase 2)

ras Proteins (Phase 2)

Sarcoma (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 1/Phase 2)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 47
  • # of Trial Organizations: 22

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue